Updates on the Diagnosis and Management of Glaucoma

Wagner, Isabella V.; Stewart, Michael W.; Dorairaj, Syril

doi:10.1016/j.mayocpiqo.2022.09.007

Cited by 55 publications

(48 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reduced risk of POAG is in agreement with the well established intraocular pressure reduction by BBs through blockade of sympathetic nerve endings in the ciliary epithelium. This causes a fall in aqueous humor production and makes topical therapy with BBs a mainstay in glaucoma management [1569]. In this regard, it is worthwhile mentioning that topical treatment of glaucoma with BBs may also induce systemic effects, including side effects such as bradycardia, due to absorption of the drugs [1570].…”

Section: Hypertension and Other Selected Comorbiditiesmentioning

confidence: 99%

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Chairperson

Co-Chair

Brunström

et al. 2023

Journal of Hypertension

1,096

280

View full text Add to dashboard Cite

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis (Greece), Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine (Turkey), Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering (Poland), Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos (Greece), Kazuomi Kario (Japan), Vasilios Kotsis (Greece), Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack (UK), Paolo Mulatero (Italy), Dike B. Ojji (Nigeria), Sungha Park (South Korea), Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz (Poland), Venkata Ram (India), Ramiro Sanchez (Argentina), Markus Schlaich (Australia), Alta Schutte (Australia), Cristina Sierra (Spain), Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios (Greece), Bruno Trimarco (Italy), Thomas Unger (The Netherlands), Bert-Jan van den Born (The Netherlands), Anna Vachulova (Slovak Republic), Agostino Virdis (Italy), Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton (USA), Jiri Widimsky (Czech Republic), Jacek Wolf (Poland), Grégoire Wuerzner (Switzerland), Eugene Yang (USA), Yuqing Zhang (China).

show abstract

Section: Hypertension and Other Selected Comorbiditiesmentioning

confidence: 99%

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Chairperson

Co-Chair

Brunström

et al. 2023

Journal of Hypertension

1,096

280

View full text Add to dashboard Cite

show abstract

“…[49] Glaucoma is often divided into two main categories: open angle and angle-closure. [49] In most cases, a dysfunction in the ocular drainage system leads to a buildup of fluid, ultimately leading to an excessive increase in intraocular pressure (IOP). [49] Presently, eye drops constitute the most common form of glaucoma management.…”

Section: Glaucomamentioning

confidence: 99%

“…[49] In most cases, a dysfunction in the ocular drainage system leads to a buildup of fluid, ultimately leading to an excessive increase in intraocular pressure (IOP). [49] Presently, eye drops constitute the most common form of glaucoma management. [50] However, penetration into the deeper tissues of the eyes remains a challenge with this method.…”

Section: Glaucomamentioning

confidence: 99%

See 1 more Smart Citation

Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications

Kulbay,

Wu,

Truong

et al. 2024

Smart Molecules

View full text Add to dashboard Cite

This comprehensive review delves into a unique intersection of hydrogels as smart molecules and their transformative applications in ophthalmology. Beginning with the foundational definition, properties, and classification of hydrogels, the review explores their synthesis and responsive capabilities. Specific applications examined encompass topical drug delivery, contact lenses, intravitreal drug delivery, ocular adhesives, vitreous substitutes, and cell‐based therapy. A methodical analysis, including an overview of relevant ocular structures and a comparative evaluation of hydrogel‐based solutions against traditional treatments, is conducted. Additionally, potential constraints, translation challenges, knowledge gaps, and research areas are identified. Our methodical approach, guided by an extensive literature review from 2017 to 2023, illuminates the unprecedented opportunities offered by hydrogels, along with pinpointing areas for further inquiry to facilitate their transition into clinical practice.

show abstract

“…Glaucoma is a degenerative disease that requires lifetime drug treatment and can be acute or chronic [ 1 ]. A blockage in the flow of aqueous humor between the front and back of the eye causes intraocular pressure to rise quickly, retinal degeneration, and optic neuropathy, all of which are signs of acute glaucoma [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma

et al. 2023

View full text Add to dashboard Cite

Glaucoma is a degenerative, chronic ocular disease that causes irreversible vision loss. The major symptom of glaucoma is high intraocular pressure, which happens when the flow of aqueous humor between the front and back of the eye is blocked. Glaucoma therapy is challenging because of the low bioavailability of drugs from conventional ocular drug delivery systems such as eye drops, ointments, and gels. The low bioavailability of antiglaucoma agents could be due to the precorneal and corneal barriers as well as the low biopharmaceutical attributes of the drugs. These limitations can be overcome by employing nanoparticulate drug delivery systems. Over the last decade, there has been a lot of interest in chitosan-based nanoparticulate systems to overcome the limitations (such as poor residence time, low corneal permeability, etc.) associated with conventional ocular pharmaceutical products. Therefore, the main aim of the present manuscript is to review the recent research work involving the chitosan-based nanoparticulate system to treat glaucoma. It discusses the significance of the chitosan-based nanoparticulate system, which provides mucoadhesion to improve the residence time of drugs and their ocular bioavailability. Furthermore, different types of chitosan-based nanoparticulate systems are also discussed, namely nanoparticles of chitosan core only, nanoparticles coated with chitosan, and hybrid nanoparticles of chitosan. The manuscript also provides a critical analysis of contemporary research related to the impact of this chitosan-based nanomedicine on the corneal permeability, ocular bioavailability, and therapeutic performance of loaded antiglaucoma agents.

show abstract

Updates on the Diagnosis and Management of Glaucoma

Cited by 55 publications

References 112 publications

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications

Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma

Contact Info

Product

Resources

About